Safety and Performance of a Synthetic Tissue Sealant in Reducing Fluid Leakage in Hepatobiliary and Pancreatic Surgery

Pancreatectomy Clinical Trial

— SHIELDS  

Official title:

Prospective, Multicenter Study to Evaluate the Safety and Performance of a syntHetic Tissue Sealant in Reducing fluId lEakage Following Elective hepatobiLiary anD Pancreatic Surgery

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04024956
• Other study ID #: CIP-3
• Status: Completed
• Phase: N/A
• Start date: August 25, 2020
• Est. completion date: May 26, 2023

Study information

• Verified date: June 2023
• Source: Polyganics BV
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Polyganics BV (Groningen, The Netherlands), in close collaboration with University Hospital-Eppendorf (UKE) Hamburg, has developed the Sealing Device for use in hepato-pancreato-bilary (HPB) surgery to reduce leakage of fluids from the site of surgery into the abdominal cavity and as an adjunctive hemostatic device to control minimal to moderate bleeding at the surgical site. The Sealing Device has been challenged in pre-clinical testing (laboratory and in-vivo work), but has not been evaluated for safety and performance in humans. This investigation will be conducted to clinically assess the safety and performance of Sealing Device as a means to reduce bile and pancreatic juice leakage in hepato-pancreato-bilary (HPB) surgery. Secondarily, the control of minimal to moderate bleeding will be assessed. To achieve adequate representation of the primary objective, the study will contain two separate surgical patient groups: Liver and Pancreas. The primary objective of the study is to demonstrate safety and performance in reducing intra- and post-operative leakage (bile and pancreatic juices) by using the Sealing Device in patients undergoing elective hepatic resection or distal pancreatectomy. The study will be conducted as an open-label, single-arm, multicenter study with a 16 months follow up. Up to 80 patients (40 liver and 40 pancreas patients) will be enrolled at up to 7 sites in Europe.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 80
• Est. completion date: May 26, 2023
• Est. primary completion date: November 19, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Preoperative inclusion criteria:

Subjects will be eligible according the following criteria:

1. Subjects who are able to provide a written informed consent prior to participating in the clinical investigation.

2. Subjects who are = 18 years old.

3. Subjects who are able to comply with the follow-up or other requirements.

4. Subjects who are planned for an elective hepatic resection or distal pancreatectomy. During the surgery, the patients also need to comply with the intraoperative criteria. Intraoperative inclusion criteria:

Subjects will be eligible according the following criteria:

1. Patch is applied manually (during open procedure, conversion procedure, or laparoscopic assisted procedure). Exclusion Criteria: Preoperative exclusion criteria

Subjects who meet any of the following criteria will be excluded from participation:

1. Female subjects who are pregnant and/or breastfeeding.

2. Subjects with a known allergy to any of the components of the Sealing Device (Polyurethane (SDPU), 8-ArmPEG40k-SC (SDA), Disodium Hydrogen Phosphate (Na2HPO4) (BS) and DC-Green #6 (SDD)).

3. Subject with bleeding disorders requiring anti-coagulation medication (except acetylsalicylic acid).

4. Subjects who receive double-coagulation.

5. Subjects who receive peritoneal dialysis.

6. Subjects who previously required liver transplantation.

7. Subjects with a presence of systemic infection.

8. Subject who previously participated in this study, or in any investigational drug- or device study within 30 days of screening.

9. Subjects undergoing a procedure requiring an anastomosis (e.g. Klatskin tumours or Whipple). Intraoperative exclusion criteria:

Subjects who meet any of the following criteria will be excluded from participation:

1. Subjects with multivisceral resections, except resection of spleen.

2. Not able to apply the patch(es) according to the Instructions For Use.

3. Total surgery requiring > 3 HPB Sealing Devices of 10 x 5 cm (which equals a resection surface of more than 88cm2).

Additional for liver group:

4. Subjects with a Grade 3 or 4 of bleeding after primary closure after liver transection (Lewis 2016).

5. Subjects with liver cirrhosis Grade C on the Child-Turcotte-Pugh score.

Additional for pancreas group:

6. Subjects with a margin of < 1 cm between the defect and the portal vein.

Related Conditions & MeSH terms

• Hepatic Resection
• Pancreatectomy

Intervention

Device:
• Sealing Device
The Sealing Device is indicated for use in hepato-pancreato-biliary (HPB) surgery to reduce leakage of fluids from the site of surgery into the abdominal cavity and as an adjunctive hemostatic device to control minimal to moderate bleeding at the surgical site.

Locations

Country	Name	City	State
Germany	Universitats Klinikum Hamburg-Eppendorf	Hamburg
Germany	University Hospital Oldenburg	Oldenburg

Sponsors (2)

Lead Sponsor	Collaborator
Polyganics BV	Genae

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Bile leakage	Incidence of post-operative bile leakage (International Study Group of Liver Surgery Bile leakage Grading Scale); categories in order of ascending severity: biochemical leak, Grade B or Grade C	30 days
Primary	Pancreatic leakage	Incidence of post-operative pancreatic juice leakage (International Study Group of Pancreas Surgery Grading Scale); categories in order of ascending severity: biochemical leak, Grade B or Grade C	30 days
Secondary	Bleeding	Intra-operative control bleeding	Day 1
Secondary	Leak-associated comorbidities	Incidence of leak-associated comorbidities	16 months
Secondary	re-intervention	Incidence of re-intervention	16 months
Secondary	Ease of Use	Ease of Use of the device as measured by questionnaire	Day 1
Secondary	Post-operative bile leakage	Incidence of post-operative bile leakage (liver only)	90 and 180 days
Secondary	Post-hepatectomy haemorrhage (PHH)	Incidence of post-operative bleeding (liver only)	30 days
Secondary	Post-operative pancreatic juice leakage	Incidence of post-operative pancreatic juice leakage (pancreas only)	90 and 180 days
Secondary	Post-pancreatectomy haemorrhage (PPH)	Incidence of post-operative bleeding (pancreas only)	30 days
Secondary	(Serious) Adverse Device Effects	Incidence of (Serious) Adverse Device Effects	16 months
Secondary	Incidence of transfusion	Incidence of transfusion	16 months
Secondary	Length of hospital stay	Length of hospital stay	30 days